gastric cancer
Conditions
Interventions
Case series:No
Sponsors
Linfen Central Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18 to 75 years, male or female; 2. Advanced gastric or gastroesophageal junction adenocarcinoma diagnosed by pathology with measurable lesions (spiral CT scan >=10mm, meeting RECIST 1.1 criteria); 3. ECOG PS: 0-2 points; 4. Main organs function normally and meet the following requirements: (1) Routine blood examination, must meet (no blood transfusion within 14 days) : 1) HB 80 g/L or higher; 2) The ANC acuity 1.5 x 10^9 / L; 3) PLT acuity 80 x 10^9 / L. (2) Biochemical examination shall meet the following standards: 1) BIL=50ml/min (Cockcroft-Gault formula). 5. Expected survival >=3 months; 6. The operation has been performed for more than 4 weeks and the wound has completely healed; 7. Women of childbearing age must have a negative pregnancy test (serum or urine) within 7 days before enrolment and voluntarily use appropriate methods of contraception during the observation period and within 8 weeks after the last administration of apatinib;For men, they should be surgically sterilized or agree to use an appropriate method of contraception during the observation period and for 8 weeks after the last administration of apatinib tablets; 8. Patients voluntarily participated in this study and signed informed consent (ICF) with good compliance and follow-up.
Exclusion criteria
Exclusion criteria: 1. Patients with hypertension that cannot be reduced to the normal range after antihypertensive drug treatment (systolic blood pressure >140 mmHg/diastolic blood pressure > 90 mmHg), coronary heart disease (>=ii), arrhythmias (including QTC extended > 450 ms in men and > 470 ms in women) and cardiac insufficiency; 2. There are many factors that affect oral medication (such as inability to swallow, chronic diarrhea and intestinal obstruction, etc.); 3. Abnormal coagulation function and bleeding tendency; 4. Symptomatic central nervous system metastases; 5. Pregnant or lactating women; 6. Other patients deemed unsuitable for inclusion by physicians.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| progression-free survival; | — |
Countries
China
Contacts
Public ContactLi Yanli
Linfen Central Hospital
Outcome results
None listed